Creation of a Hit-To-Lead Medicinal Chemistry Tender - 139419741

Procurement Summary

Country: France

Summary: Creation of a Hit-To-Lead Medicinal Chemistry Program for the Development of Chemical Compounds Acting as Allosteric Modulators of a Kinase Identified as a Therapeutic Target

Deadline: 13 Jun 2026

Posting Date: 12 Apr 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 139419741

Document Ref. No.: 26-37016

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

CPV Classification

33661000 - Medicinal products for the nervous system

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

Protein kinase X plays a key role in different signaling pathways involved in the progression of a rare disease. It has been observed that kinase X is overactivated in cells affected by the disease. Interestingly, inhibition of its activity by small chemical compounds induces beneficial effects in vitro and in vivo in a mouse model of the disease. For all of these reasons, protein kinase X is currently considered a promising therapeutic target. There structure 3D de la protéine kinase X a été déterminée et est disponible dans les bases de données protéiques (ex. : RSCB PDB). Based on biochemical and structural studies, an allosteric domain was identified. Its targeting by small molecules can influence positively (positive allosteric modulators) or negatively (negative allosteric modulators) the activity of the kinase on its different substrates. Among the chemical compounds tested, an allosteric modulator was selected for (i) its ability to bind specifically to or near this domain of the enzyme and (ii) its biological action in vitro. By capitalizing on this hit, the objective of the DK-One TherapeutiX project is to improve its performance by introducing chemical diversity. The new molecules derived from the hit will be designed, synthesized and screened in vitro by the holder.

Documents

 Tender Notice